Biotech, VC, Life Sciences Luke Timmerman wrote: There are easier things to do these days than trying to organize a biotech investing conference in Seattle. The local cluster has taken its share of body blows, the weather is usually pretty gray in late winter, and investors aren’t in the mood ...

Biotech, cancer, deals Luke Timmerman wrote: The recession will surely kill off some biotech companies that lack hard cash and the hard data that shows their experimental drugs can improve patients’ lives. But after I heard Seattle Genetics CEO Clay Siegall tell the story of how his company ra...

Biotech, Devices, people Luke Timmerman wrote: Tom Clement was the founding engineer who started Kirkland, WA-based Pathway Medical Technologies a decade ago, resurrected it after a setback in treating heart disease, and reinvented it around a modified device to clear out clogged arteries in the leg...

Biotech, Hepatitis C, Life Sciences Luke Timmerman wrote: An early peek at data from Anadys Pharmaceuticals (NASDAQ: ANDS) suggests the company may have a promising new drug in the works for hepatitis C. The San Diego-based biotech is announcing results today from the first eight patients with the c...